Aura Biosciences (AURA) Other Operating Expenses (2021 - 2022)
Aura Biosciences' (AURA) quarterly Other Operating Expenses came in at -$313000.0 in Q3 2022, down 6160.0% on a QoQ basis from -$5000.0 in Q1 2022.
Analysis
Aura Biosciences (AURA) Other Operating Expenses (2021 - 2022) Analysis & Trends
Aura Biosciences (AURA) has 2 years of Other Operating Expenses data on file, last reported at -$313000.0 in Q3 2022.
- Quarterly Other Operating Expenses changed N/A year-over-year to -$313000.0 in Q3 2022, while the trailing twelve-month figure through Jun 2023 was -$313000.0 (down 6160.0% YoY) and the FY2023 annual result came in at $208000.0, up 165.41% from the prior year.
- Other Operating Expenses slipped to -$313000.0 in Q3 2022, from -$5000.0 in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of -$3000.0 in Q1 2021 to a low of -$313000.0 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Aura Biosciences | 711.48 Mn | 643.64 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | -313,000.00 |
| Mar 31, 2022 | -5,000.00 |
| Mar 31, 2021 | -3,000.00 |